# Gilgamesh Pharma

> Gilgamesh Pharma is an independent clinical-stage neuroscience company developing novel psychiatric medicines. Following the 2025 sale of the predecessor company and its bretisilocin program to AbbVie, the team retained blixeprodil, an investigational oral NMDA receptor antagonist for depression, and other discovery programs. It combines medicinal chemistry, translational neuroscience and computational tools, funded through venture capital, research grants and pharmaceutical partnerships.

- **Founded:** 2019
- **Headquarters:** New York, United States
- **Founders:** Jonathan Sporn (Co-founder and CEO), Andrew Kruegel (Co-founder and CSO), Dalibor Sames (Co-founder), Michael Cunningham (Co-founder, scientist), Jeffrey Witkin (Co-founder, preclinical pharmacologist)
- **Products:** Blixeprodil (GM-1020), Non-hallucinogenic neuroplastogens, GM-3009, M1/M4 agonist program, Bretisilocin (GM-2505; now ABBV-2505)
- **Notable:** Positive company-reported Phase 2a results for bretisilocin in May 2025., AbbVie completed its acquisition in October 2025 after the remaining programs and team spun out; $906 million upfront and up to $300 million contingent development payments in AbbVie filings., Positive company-reported Phase 2a results for blixeprodil announced January 2026.

## Products & services

- **Blixeprodil (GM-1020)** — Investigational oral, non-competitive NMDA receptor antagonist for major depressive disorder; positive Phase 2a topline results announced January 2026.
- **Non-hallucinogenic neuroplastogens** — Novel compounds intended to promote brain plasticity, covered by an ongoing AbbVie collaboration and option-to-license agreement.
- **GM-3009** — Investigational ibogaine analog designed to reduce cardiac risk; NIDA funding supports toxicology, manufacturing and early clinical development for opioid use disorder.
- **M1/M4 agonist program** — Investigational oral muscarinic receptor agonist program targeting schizophrenia; company emphasizes selectivity and reduced peripheral adverse effects.
- **Bretisilocin (GM-2505; now ABBV-2505)** — Historical Gilgamesh program: short-acting serotonergic psychedelic for major depressive disorder, acquired by AbbVie in October 2025. Not owned by the independent Gilgamesh Pharma.

## Achievements

- Positive company-reported Phase 2a results for bretisilocin in May 2025.
- AbbVie completed its acquisition in October 2025 after the remaining programs and team spun out; $906 million upfront and up to $300 million contingent development payments in AbbVie filings.
- Positive company-reported Phase 2a results for blixeprodil announced January 2026.
- Selected for Fierce Biotech’s 2024 Fierce 15.
- Closed a $60 million independent-spinout Series A in March 2026.

## Latest updates

- **2026-03** — Announced $60 million Series A led by Satori Neuro with Prime Movers Lab participating; blixeprodil expected to enter late-stage development in 2026, a forward-looking plan.
- **2026-01** — Reported blixeprodil Phase 2a proof-of-concept results in 46 MDD patients; 6.3-point placebo-adjusted MADRS advantage at 24 hours, p=0.006.
- **2025-10** — AbbVie completed bretisilocin acquisition; independent Gilgamesh Pharma retained employees, other programs and the neuroplastogen option agreement.

## Links

- Website: https://www.gilgameshpharmaceutical.com/
- LinkedIn: https://www.linkedin.com/company/gilgamesh-pharma
- Twitter/X: https://twitter.com/gilgameshrx

---

Profile page: https://yespress.io/gilgamesh-pharma
Published by YesPress — https://yespress.io
Last updated: 2026-10-03